Myriad Genetics Inc (MYGN) · Nov 5, 2026 · Cybersecurity
Cyber incident
Myriad Genetics disclosed a cyberattack that temporarily suspended testing and order systems. Operations are mostly restored, but the patient-data investigation is unfinished.
Myriad is trying to shift its business toward the cancer-care continuum while streamlining operations and selling its prenatal-testing unit to focus capital and attention on that strategy.
The incident temporarily hit core operating systems, not just back-office infrastructure. Myriad said it suspended testing operations and order-management systems while resetting credentials and investigating unauthorized access. 〔0〕
The immediate disruption appears contained, but the important risk is unresolved. Most systems have returned to normal, and management currently believes there will be no material business impact; however, the company has not finished determining whether patient records were accessed. 〔1〕 〔2〕
That makes this a modest setback to execution rather than a rewritten business story. The filing does not disclose a confirmed material loss, prolonged outage, or known patient-data breach, but it adds operational, regulatory, legal, and reputational uncertainty while Myriad is already navigating a strategic transition.
Bottom line: Myriad has restored most systems, but the cyber incident is not fully understood. Until the patient-data and business-impact assessment is complete, it modestly clouds an otherwise active operating transition rather than changing the company’s overall direction.
Forensic investigation and patient-data assessment
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!